• United States

U.S. Biotech Stock News

NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

January 27, 2023
Key Insights MannKind's estimated fair value is US$8.9 based on 2 Stage Free Cash Flow to Equity Current share price of...
NasdaqGS:HOWL
NasdaqGS:HOWLBiotechs

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

January 27, 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqCM:MDXG
NasdaqCM:MDXGBiotechs

More money in the bank for insiders who divested US$1.7m worth of MiMedx Group, Inc. (NASDAQ:MDXG) shares last year

January 27, 2023
Despite the fact that MiMedx Group, Inc. (NASDAQ:MDXG) stock rose 12% last week, insiders who sold US$1.7m worth of...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Bullish Ardelyx, Inc. (NASDAQ:ARDX) insiders were rewarded last week as their US$1.0m investment inflated to US$1.9m

January 26, 2023
Ardelyx, Inc. ( NASDAQ:ARDX ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
NasdaqGS:SGEN
NasdaqGS:SGENBiotechs

Seagen Inc.'s (NASDAQ:SGEN) large institutional owners must be happy as stock continues to impress, up 4.6% over the past week

January 26, 2023
Key Insights Significantly high institutional ownership implies Seagen's stock prices are sensitive to their trading...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

January 26, 2023
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
NasdaqGS:RXDX
NasdaqGS:RXDXBiotechs

Prometheus Biosciences' Investors Sitting On Solid 262% Return Over Year

January 26, 2023
Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
NasdaqGS:XLO
NasdaqGS:XLOBiotechs

Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most

January 26, 2023
If you want to know who really controls Xilio Therapeutics, Inc. ( NASDAQ:XLO ), then you'll have to look at the makeup...
NasdaqGM:INAB
NasdaqGM:INABBiotechs

Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?

January 26, 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although...
NasdaqGS:ABSI
NasdaqGS:ABSIBiotechs

Following 27% Rise Last Week, Absci Shareholders Still Down 49% Over Past Year

January 26, 2023
Absci Corporation ( NASDAQ:ABSI ) shareholders will doubtless be very grateful to see the share price up 50% in the...
NasdaqGS:MGNX
NasdaqGS:MGNXBiotechs

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

January 25, 2023
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqGM:GRNA
NasdaqGM:GRNABiotechs

Private equity firms are GreenLight Biosciences Holdings' (NASDAQ:GRNA) biggest owners and were hit after market cap dropped US$21m

January 25, 2023
Key Insights Significant control over GreenLight Biosciences Holdings by vc/pe firms implies that this group likely has...
NasdaqCM:IKT
NasdaqCM:IKTBiotechs

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

January 25, 2023
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Is The Market Wrong About Catalyst Pharmaceuticals?

January 25, 2023
With its stock down 21% over the past week, it is easy to disregard Catalyst Pharmaceuticals (NASDAQ:CPRX). However, a...
NasdaqCM:EPIX
NasdaqCM:EPIXBiotechs

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

January 25, 2023
Key Insights ESSA Pharma's estimated fair value is US$3.4 based on 2 Stage Free Cash Flow to Equity Current share price...
NasdaqGS:ORIC
NasdaqGS:ORICBiotechs

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

January 24, 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

January 24, 2023
Key Insights Arrowhead Pharmaceuticals' estimated fair value is US$31.2 based on 2 Stage Free Cash Flow to Equity...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Moderna Rallies 3.3% This Week, Taking Three-Year Gains To 781%

January 24, 2023
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for...
NasdaqGM:PRME
NasdaqGM:PRMEBiotechs

Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?

January 24, 2023
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqCM:BWV
NasdaqCM:BWVBiotechs

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

January 24, 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NasdaqCM:AZYO
NasdaqCM:AZYOBiotechs

Despite recent gains, Aziyo Biologics, Inc. (NASDAQ:AZYO) insiders are still down US$3.0k after purchasing last year

January 24, 2023
Insiders who bought US$146k worth of Aziyo Biologics, Inc. ( NASDAQ:AZYO ) stock in the last year recovered part of...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Despite Viking Therapeutics, Inc.'s recent decline, insiders have made a around US$269k profit after buying earlier this year.

January 24, 2023
Viking Therapeutics, Inc. ( NASDAQ:VKTX ) insiders who acquired shares over the previous 12 months, can probably afford...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?

January 24, 2023
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) is possibly approaching a major achievement in its business, so we would...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Insiders Relieved After Selling Recursion Pharmaceuticals With 5.1% Price Dip

January 24, 2023
By selling US$164k worth of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) stock at an average sell price of US$8.77...
  • 1
  • 2
  • 3
  • 4
  • 5
Next

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.

Home

Markets

Discover

Watchlist

Portfolios

Screener
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
  • About
  • Careers
  • Plans
  • Log In
  • Help Centre
  • Latest Coverage
  • Podcasts
  • Financial Services Guide
  • Terms and Conditions
  • Privacy Policy

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.